24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

Hypercalcemic Crisis: Pathophysiology & Clinical Presentation

Calcium homeostasis is tightly regulated within a narrow physiologic range (normal total serum calcium: 8.5 to 10.5 mg/dL; ionized calcium: 1.15 to 1.35 mmol/L) through the coordinated actions of parathyroid hormone (PTH), 1,25-dihydroxyvitamin D (calcitriol), and calcitonin on bone, kidneys, and the gastrointestinal tract. Approximately 40% to 45% of circulating calcium is bound to plasma proteins (primarily albumin), 10% is complexed with anions (phosphate, citrate), and 45% to 50% circulates as physiologically active, free ionized calcium.

Corrected Calcium Formula

Because routine chemistry panels measure total calcium, hypoalbuminemia falsely depresses the measured value:

Corrected Total Calcium (mg/dL) = Measured Total Calcium + 0.8 x (4.0 - Serum Albumin [g/dL])

Clinical Caveat: In critically ill patients, cirrhotics, or patients with acid-base disturbances, the formula is inaccurate; direct measurement of ionized calcium is the clinical gold standard.

Severity Classification

• Mild Hypercalcemia: Total calcium 10.5 to 11.9 mg/dL (often asymptomatic or mild constipation)
• Moderate Hypercalcemia: Total calcium 12.0 to 13.9 mg/dL (fatigue, polyuria, anorexia)
• Hypercalcemic Crisis (Severe): Total calcium >=14.0 mg/dL (or ionized calcium >3.0 mmol/L). Represents an acute medical emergency characterized by life-threatening dehydration, renal failure, cardiac dysrhythmias, and progressive encephalopathy.

Clinical Manifestations: "Stones, Bones, Abdominal Groans, Thrones & Psychiatric Overtones"

• Renal ("Stones & Thrones"):
  • Nephrogenic Diabetes Insipidus (NDI): Hypercalcemia activates calcium-sensing receptors (CaSR) in the basolateral membrane of the collecting duct, inducing endocytosis and downregulation of aquaporin-2 water channels. This causes severe polyuria, nocturia, and polydipsia refractory to ADH.
  • Calcium additionally interferes with the countercurrent multiplier mechanism in the thick ascending limb of Henle.
  • Nephrolithiasis (calcium oxalate/phosphate stones), nephrocalcinosis, and pre-renal azotemia from profound fluid deficits (typically 3 to 5 liters).
• Gastrointestinal ("Abdominal Groans"):
  • Severe constipation, nausea, intractable vomiting, and anorexia.
  • Acute Pancreatitis: Elevated calcium activates intra-acinar trypsinogen into active trypsin, precipitating autodigestive pancreatic necrosis.
  • Peptic Ulcer Disease: Calcium directly stimulates gastrin hypersecretion from G cells and gastric acid production by parietal cells.
• Neurological ("Psychiatric Overtones"):
  • Progressive neuromuscular depression: muscle weakness, hyporeflexia, cognitive slowing, anxiety, depression, acute delirium, psychosis, stupor, and coma.
• Cardiovascular Manifestations:
  • Shortened QT interval on ECG (accelerated phase 2 plateau of the myocyte action potential);
  • Cardiac arrhythmias, increased vascular tone (hypertension), and heightened vulnerability to digitalis toxicity.

Etiology: Primary Hyperparathyroidism versus Malignancy

Together, primary hyperparathyroidism and malignancy account for >90% of all hypercalcemia cases:

                  DIFFERENTIAL DIAGNOSIS OF HYPERCALCEMIA

     PRIMARY HYPERPARATHYROIDISM                     HYPERCALCEMIA OF MALIGNANCY
  (Most common outpatient, 90% of clinic)         (Most common inpatient, 80% of ICU)
  ┌────────────────────────────────────┐          ┌────────────────────────────────────┐
  │ • Intact PTH: ELEVATED or          │          │ • Intact PTH: SUPPRESSED (<10 pg)  │
  │   inappropriately normal           │          │ • Rapid onset, severe (Ca >14 mg)  │
  │ • Serum Phosphate: Low or normal   │          │ • 3 Mechanisms:                    │
  │ • 1,25-(OH)2D: Normal or elevated  │          │   1. PTHrP secretion (80%)         │
  │ • Solitary adenoma (85%),          │          │      Squamous cell (lung/head/neck)│
  │   hyperplasia (15%), carcinoma (<1%)│         │   2. Osteolytic metastases (20%)   │
  │ • Indolent, mild-to-moderate       │          │      Multiple myeloma, breast      │
  │ • Treatment: Parathyroidectomy     │          │   3. Calcitriol excess (1%)        │
  │                                    │          │      Lymphomas, Sarcoidosis        │
  └────────────────────────────────────┘          └────────────────────────────────────┘

1. Humoral Hypercalcemia of Malignancy (HHM - 80% of cancer cases):
   • Tumors secrete Parathyroid Hormone-Related Protein (PTHrP), which binds to and activates common PTH1 receptors in bone and kidney.
   • Stimulates osteoclast resorption and renal calcium retention without stimulating renal 1-alpha-hydroxylase (thus calcitriol is low/normal).
   • Classic malignancies: Squamous cell carcinomas (lung, head and neck, esophagus), renal cell carcinoma, ovarian carcinoma.
2. Local Osteolytic Hypercalcemia (20% of cancer cases):
   • Extensive skeletal metastases or marrow infiltration: Multiple myeloma, metastatic breast cancer, non-small cell lung cancer.
   • Malignant cells release local cytokines (RANKL, IL-1, IL-6, TNF-alpha) driving profound osteoclast-mediated bone destruction.
3. 1,25-Dihydroxyvitamin D (Calcitriol) Overproduction (1% of cancer cases):
   • Autonomous extra-renal 1-alpha-hydroxylase expression in tumor-associated macrophages.
   • Seen in Hodgkin and non-Hodgkin lymphomas and non-malignant granulomatous disorders (Sarcoidosis, tuberculosis, berylliosis).

---

Hypercalcemia Emergency Pharmacotherapy Protocol

                     STEPWISE HYPERCALCEMIA MANAGEMENT

    STEP 1: SALINE RESUSCITATION          STEP 2: CALCITONIN BRIDGE
  ┌──────────────────────────────┐     ┌──────────────────────────────┐
  │ • 0.9% Normal Saline IV      │     │ • Salmon Calcitonin          │
  │ • 1000-2000 mL over 1-2 h    │ ──► │   4-8 IU/kg SC/IM q12h       │
  │ • Maintenance: 200-500 mL/h  │     │ • Onset: 2-4 hours           │
  │ • Enhances renal calciuresis │     │ • Tachyphylaxis in 48 hours  │
  │ • NO FUROSEMIDE acutely!     │     │ • Bridges until bisphosphonate│
  └──────────────────────────────┘     └──────────────────────────────┘
                 │
                 ▼
    STEP 3: BISPHOSPHONATE                STEP 4: SPECIALTY AGENTS
  ┌──────────────────────────────┐     ┌──────────────────────────────┐
  │ • Zoledronic Acid 4 mg IV    │     │ • Denosumab (RANKL Ab) 120mg │
  │   infused over 15 minutes    │     │   (If GFR <30 mL/min or      │
  │ • Inhibits osteoclasts       │ ──► │    refractory to zoledronate)│
  │ • Onset: 2-4 days            │     │ • Corticosteroids (Prednisone│
  │ • Nadir: 4-7 days            │     │   40-60mg for lymphoma/sarco)│
  │ • Avoid if GFR <30 mL/min    │     │ • Hemodialysis (if Ca >18)   │
  └──────────────────────────────┘     └──────────────────────────────┘

Step 1: Aggressive Volume Resuscitation (Isotonic Normal Saline)

• Rationale: Patients in hypercalcemic crisis are universally and profoundly dehydrated (3 to 5 L fluid deficit) secondary to nephrogenic diabetes insipidus, vomiting, and decreased intake.
• Administration Protocol:
  • Initial Bolus: 0.9% Normal Saline at 1000 to 2000 mL IV over the first 1 to 2 hours.
  • Maintenance Infusion: Continue normal saline at 200 to 500 mL/h, titrating to maintain a robust urine output of 100 to 150 mL/h.
  • Mechanism: Normal saline expands intravascular volume, restores GFR, and increases distal sodium and fluid delivery. In the thick ascending limb of Henle, calcium reabsorption is passively linked to sodium reabsorption; inducing natriuresis directly promotes passive renal calcium excretion.
  • Expected Effect: Lowers serum calcium by 1.5 to 3.0 mg/dL within 24 to 48 hours.
• The Critical Loop Diuretic Warning:
  • Furosemide is CONTRAINDICATED in the initial management of hypercalcemic crisis.
  • Administering a loop diuretic to a volume-depleted hypercalcemic patient worsens hypovolemia, decreases GFR, and paradoxically elevates serum calcium.
  • Loop diuretics are indicated strictly after the patient is completely euvolemic, and only if signs of volume overload (pulmonary edema, heart failure) emerge.

Step 2: Calcitonin (The Immediate Bridge)

• Dose: Salmon Calcitonin 4 to 8 IU/kg SC or IM every 12 hours.
• Mechanism: Binds calcitonin receptors on osteoclasts, acutely inhibiting bone resorption; also promotes renal calcium clearance.
• Pharmacodynamics:
  • Rapid onset within 2 to 4 hours; lowers serum calcium by 1 to 2 mg/dL.
  • Crucial Limitation: Tachyphylaxis develops within 48 hours due to rapid downregulation and internalization of calcitonin receptors on osteoclast surfaces. Calcitonin serves exclusively as a rapid, temporary bridge while awaiting the onset of bisphosphonates.

Step 3: Intravenous Bisphosphonates (Definitive Long-Acting Therapy)

• Agent of Choice: Zoledronic Acid 4 mg IV infused over at least 15 minutes (superior efficacy and longer duration of action compared to pamidronate 60-90 mg IV infused over 2-4 hours).
• Mechanism: Pyrophosphate analog that binds hydroxyapatite crystals in mineralized bone, entering osteoclasts and inhibiting farnesyl pyrophosphate synthase, inducing osteoclast apoptosis and blocking osteolytic bone resorption.
• Pharmacodynamics:
  • Onset of action is 2 to 4 days; nadir of serum calcium occurs at 4 to 7 days; duration of normocalcemia lasts 2 to 4 weeks.
• Safety in Renal Impairment:
  • Bisphosphonates are excreted renally and can cause acute tubular necrosis. Zoledronic acid requires caution and dose adjustment in chronic kidney disease and is generally contraindicated when serum creatinine is >4.5 mg/dL or GFR is <30 mL/min.

Step 4: Denosumab (RANKL Inhibitor)

• Dose: Denosumab 120 mg subcutaneously (with additional 120 mg loading doses on days 8 and 15 in refractory malignancy).
• Mechanism: Fully human monoclonal antibody that binds and neutralizes RANKL (Receptor Activator of Nuclear Factor-kB Ligand), preventing RANKL from binding to its receptor RANK on osteoclast precursors. This completely arrests osteoclast proliferation, differentiation, and survival.
• Clinical Indications:
  1. Severe Renal Impairment: Denosumab is not cleared by the kidneys and can be safely administered in patients with GFR <30 mL/min or on hemodialysis where bisphosphonates are contraindicated;
  2. Bisphosphonate-Refractory Hypercalcemia of Malignancy.

Step 5: Corticosteroids

• Indication: Hypercalcemia mediated by 1,25-dihydroxyvitamin D (calcitriol) excess (Hodgkin and non-Hodgkin lymphoma, sarcoidosis, tuberculosis, berylliosis).
• Dosing: Prednisone 40 to 60 mg orally daily (or IV Hydrocortisone 100 mg q8h).
• Mechanism: Inhibits 1-alpha-hydroxylase activity in macrophages and downregulates intestinal calcium absorption. Onset of action is 2 to 5 days.

Step 6: Emergent Hemodialysis

• Reserved for life-threatening hypercalcemia (calcium >18 to 20 mg/dL), hypercalcemia accompanied by acute oliguric renal failure, intractable pulmonary edema, or severe neurologic coma. Hemodialysis using a zero- or low-calcium dialysate bath is the most rapid clearance modality.

---\n

Severe Acute Hypocalcemia: Diagnosis, Signs & IV Calcium Replacement

Severity Classification

• Normal Total Calcium: 8.5 to 10.5 mg/dL; Ionized Calcium: 1.15 to 1.35 mmol/L
• Severe / Critical Hypocalcemia: Ionized Calcium <1.1 mmol/L (critical emergency when <0.9 mmol/L), or total calcium <7.0 mg/dL.

Neuromuscular Irritability Signs

Hypocalcemia decreases the threshold potential of excitable neurons and myocytes, causing spontaneous depolarization and repetitive axonal firing:

• Paresthesias: Early symptoms include circumoral numbness, tingling in the fingertips and toes.
• Chvostek Sign: Tapping the facial nerve trunk anterior to the external auditory meatus produces brisk ipsilateral twitching of the facial muscles (twitch of the lip, ala nasi, or orbicularis oculi). Positive in ~70% of hypocalcemic patients, but also present in ~10% of healthy individuals.
• Trousseau Sign: Inflating a sphygmomanometer blood pressure cuff to 20 mmHg above systolic blood pressure for 3 minutes produces painful carpopedal spasm (flexion of the wrist and MCP joints, extension of the IP joints, and adduction of the thumb ["obstetrician's hand"]). Trousseau sign is 94% sensitive and highly specific for latent tetany (far more reliable than Chvostek sign).
• Severe Manifestations: Laryngeal stridor, laryngospasm, bronchospasm, generalized tonic-clonic seizures, impaired cardiac contractility (congestive heart failure), and marked QTc interval prolongation predisposing to ventricular arrhythmias.

Acute Intravenous Treatment Protocol

• Agent of Choice: Intravenous Calcium Gluconate 10%:
  • Administer 1 to 2 grams (10 to 20 mL of 10% solution) diluted in 50 to 100 mL of 5% Dextrose in Water (D5W) infused IV over 10 to 20 minutes with continuous cardiac telemetry monitoring.
  • Why Calcium Gluconate over Calcium Chloride? Calcium chloride contains three times more elemental calcium, but carries an extreme risk of severe chemical thrombophlebitis and devastating full-thickness skin necrosis if extravasation into subcutaneous tissues occurs. Calcium gluconate is much safer for peripheral venous administration.
• Continuous Infusion: If hypocalcemia and tetany recur after bolus therapy, initiate a continuous infusion: add 100 mL of 10% calcium gluconate (10 ampules, ~900 mg elemental calcium) to 1000 mL D5W, infused at 50 mL/h (0.5 to 1.5 mg/kg/h).
• The Mandatory Magnesium Rule: Always check and replete serum magnesium. Hypomagnesemia suppresses PTH secretion and causes end-organ PTH resistance. Hypocalcemia is refractory to calcium repletion until hypomagnesemia is corrected.

---\n

Acute Adrenal Crisis: Etiology, Refractory Shock & Resuscitation

Acute adrenal crisis is a catastrophic, life-threatening endocrine emergency resulting from acute absolute or relative insufficiency of adrenal corticosteroids.

                    PRIMARY VS. SECONDARY ADRENAL INSUFFICIENCY

     PRIMARY ADRENAL INSUFFICIENCY                  SECONDARY / TERTIARY INSUFFICIENCY
           (Addison Disease)                               (Pituitary / Steroid Cessation)
  ┌───────────────────────────────────┐          ┌───────────────────────────────────┐
  │ • Entire Adrenal Cortex Destroyed │          │ • Pituitary ACTH Deficiency or    │
  │ • Cortisol: DEFICIENT             │          │   Abrupt Exogenous Steroid Stop   │
  │ • Aldosterone: DEFICIENT          │          │ • Cortisol: DEFICIENT             │
  │ • Etiologies: Autoimmune (80%),   │          │ • Aldosterone: PRESERVED (RAAS    │
  │   Waterhouse-Friderichsen (men-   │          │   operates independently of ACTH) │
  │   ingococcemia), Bilateral bleed  │          │ • Etiologies: Abrupt steroid stop │
  │ • Hallmarks: Hyponatremia PLUS    │          │   (most common), Sheehan, apoplexy│
  │   HYPERKALEMIA & hyperpigmentation│          │ • Hallmarks: Hyponatremia WITHOUT │
  └───────────────────────────────────┘          │   hyperkalemia; normal skin       │
                                                 └───────────────────────────────────┘

Etiology & Pathophysiology

1. Primary Adrenal Insufficiency (Addison Disease):
   • Destruction of all three zones of the adrenal cortex (zona glomerulosa, fasciculata, reticularis).
   • Results in combined glucocorticoid (cortisol) AND mineralocorticoid (aldosterone) deficiency.
   • Causes: Autoimmune adrenalitis (80% in developed countries), tuberculosis, fungal infections, bilateral adrenal metastases, and bilateral adrenal hemorrhage (Waterhouse-Friderichsen syndrome complicating Neisseria meningitidis septicemia, antiphospholipid syndrome, or heparin-induced thrombocytopenia).
2. Secondary / Tertiary Adrenal Insufficiency:
   • Failure of pituitary ACTH secretion (pituitary adenoma, surgery, radiation, Sheehan syndrome, pituitary apoplexy) or hypothalamic CRH suppression.
   • Most Common Cause: Abrupt cessation of chronic exogenous corticosteroid therapy (doses equivalent to >=20 mg prednisone daily for >3 weeks induce prolonged hypothalamic-pituitary-adrenal [HPA] axis suppression that may take up to a year to recover).
   • Key Pathophysiologic Hallmark: Mineralocorticoid secretion (aldosterone) is PRESERVED because aldosterone is regulated by the renin-angiotensin-aldosterone system (RAAS) and extracellular potassium, not pituitary ACTH.

Clinical Presentation: The Distributive Shock State

• Refractory Distributive Shock: Profound vascular collapse and hypotension completely unresponsive to vigorous volume resuscitation and high-dose vasopressors. Cortisol is an essential permissive hormone required for vascular smooth muscle alpha-1 adrenergic receptor synthesis and responsiveness; without cortisol, catecholamines cannot maintain vascular tone.
• Acute Abdomen Presentation: Severe, unremitting abdominal pain, flank pain, nausea, intractable vomiting, and abdominal guarding—frequently misdiagnosed as an acute surgical abdomen or perforated ulcer.
• High Unexplained Fever: Cortisol deficiency releases uninhibited pyrogenic cytokines (IL-1, IL-6, TNF-alpha).
• Altered Mental Status: Confusion, apathy, extreme lethargy, delirium, or coma.

Diagnostic Laboratory Pattern

Emergency Management Protocol: The "Never Delay" Rule

[!CAUTION] Cardinal Board Rule: If acute adrenal crisis is suspected, NEVER delay life-saving corticosteroid replacement to perform diagnostic confirmation! Untreated acute adrenal crisis carries a mortality approaching 100%.

1. Diagnostic Blood Draw:
   • Rapidly draw blood for baseline serum cortisol, plasma ACTH, and comprehensive metabolic panel; immediately initiate therapy without waiting for results.
2. Glucocorticoid Resuscitation:
   • First-Line Agent: Intravenous Hydrocortisone 100 mg bolus immediately, followed by 100 mg IV every 8 hours (or 200 mg continuous IV infusion over 24 hours).
   • Why Hydrocortisone? At stress doses (>=100 mg/day), hydrocortisone provides maximum glucocorticoid activity AND sufficient cross-over mineralocorticoid receptor activity to restore renal sodium conservation, rendering additional fludrocortisone unnecessary during acute resuscitation.
   • Alternative when Cosyntropin Testing is Planned: If a cosyntropin (synthetic ACTH 250 mcg) stimulation test is being performed concurrently, administer IV Dexamethasone 4 mg bolus. Dexamethasone does not cross-react with serum cortisol radioimmunoassays, permitting accurate measurement of endogenous cortisol levels. (Note: Dexamethasone has zero mineralocorticoid activity, requiring vigilant saline resuscitation).
3. Volume and Dextrose Resuscitation:
   • Administer IV 5% Dextrose in 0.9% Normal Saline (D5NS): Initial bolus of 1000 mL in the first hour, followed by maintenance infusion at 250 to 500 mL/h.
   • D5NS simultaneously accomplishes three life-saving goals: restores depleted intravascular volume, replaces total body sodium deficits, and corrects life-threatening hypoglycemia.
4. Maintenance Transition:
   • Once the patient is stabilized, hydrocortisone is tapered over 48 to 72 hours to oral maintenance doses (15-20 mg morning, 5-10 mg evening).
   • In primary adrenal insufficiency, oral Fludrocortisone (0.05 to 0.2 mg PO daily) is added only after IV hydrocortisone is tapered below 50 mg/day.